Evidence map›Paper›PMID 38607587›Full record

ReviewPharmacological reports : PR2024

Melatonin and oral diseases: possible therapeutic roles based on cellular mechanisms.

Azam Hosseinzadeh, Ali Jamshidi Naeini, Mohammad Sheibani, Babak Gholamine, Russel J Reiter, Saeed Mehrzadi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacological reports : PR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Azam HosseinzadehRazi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Ali Jamshidi NaeiniRazi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mohammad SheibaniRazi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Babak GholamineDepartment of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Russel J ReiterDepartment of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX, USA.
Saeed MehrzadiRazi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran. Sa_mehrzadi@yahoo.com.ORCID http://orcid.org/0000-0001-6619-2330
Iran University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral diseases, including periodontal disorders, oral cancer, periodontitis, and mucositis are the major challenges for both patients and healthcare providers. These conditions often involve inflammation, oxidative stress, and impaired cellular processes, leading to symptoms ranging from discomfort to severe debilitation. Conventional treatments for such oral diseases exhibit constraints, prompting the investigation of innovative therapeutic approaches. Considering the anti-inflammatory, anti-oxidant, and anti-cancer effects of melatonin, this study was carried out to investigate the potential protective effects of melatonin in mitigating the severity of oral diseases. Studies indicate that melatonin influences the differentiation of periodontal stem cells, inhibits oral cancer progression, reduces inflammation associated with periodontitis, and alleviates the severity of oral mucositis. Melatonin has demonstrated potential efficacy in both preclinical and clinical investigations; however, findings are frequently heterogeneous and contingent upon contextual factors. This review provides a comprehensiveoverview of current state of knowledge in this domain, elucidating the multifaceted role that melatonin may assume in combatingoral diseases. Further research should be directed toward determining the most effective dosing, timing, and administration methods for melatonin-based therapies for oral diseases.

Indexed as

MelatoninMouth DiseasesAnimalsAnti-Inflammatory AgentsAntioxidantsHumansOxidative StressAnti-Inflammatory AgentsAntioxidantsMelatoninInflammationMelatoninOral diseasesOxidative stressPharmacology

Identifiers

PMID38607587
OpenAlexW4394734758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.